Calidi Biotherapeutics

15 articles with Calidi Biotherapeutics

• Calidi Biotherapeutics and First Light Acquisition Group (FLAG) Announce Merger Agreement to Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies

  1/9/2023

  Calidi Biotherapeutics, Inc. and First Light Acquisition Group announced they have entered into a definitive merger agreement to create a public company focused on developing oncolytic viral therapies with stem cell-based delivery platforms to treat a wide range of cancers with significant unmet needs.

• Calidi Biotherapeutics Receives Funding from the California Institute for Regenerative Medicine (CIRM) to Advance SuperNova-1 and NeuroNova-2 Development Programs

  12/13/2022

  Calidi was awarded $3.1 million to support the development of Supernova-1 (SNV1) program through IND application.

• Calidi Biotherapeutics to Present at the 7th Annual Oncolytic Virotherapy Summit

  12/6/2022

  Calidi Biotherapeutics, Inc. today announced an upcoming presentation at the 7th Annual Oncolytic Virotherapy Summit, taking place in Boston, Massachusetts and virtually, December 6-8, 2022.

• Calidi Biotherapeutics Presents Promising Pre-Clinical Data from SuperNova-1 (SNV1), a Novel Oncolytic-Cell Based Platform, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022)

  11/7/2022

  Calidi Biotherapeutics, Inc. today announced the presentation of new pre-clinical data from the the company’s SuperNova-1 (SNV1) platform at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, taking place in Boston, Massachusetts and virtually, November 8-12, 2022.

• Calidi Biotherapeutics to Present Pre-Clinical SuperNova1 (SNV1) Data at the 2022 SITC Annual Meeting

  10/12/2022

  Calidi Biotherapeutics, Inc. today announced a poster presentation highlighting pre-clinical data from the company’s SuperNova1 (SNV1) program at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place in Boston, Massachusetts and virtually, November 8-12, 2022.

• Calidi Biotherapeutics Appoints David Sans, FAARM, Ph.D., MBA, as Head of Corporate Development

  9/28/2022

  Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company that is pioneering allogeneic cell-based platforms to revolutionize oncolytic virus therapies, today announced the appointment of David Sans, FAARM, Ph.D, MBA, in New York as Head of Corporate Development.

• Calidi Biotherapeutics to Present at Two Upcoming Conferences in September 2022

  9/8/2022

  Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company that is pioneering allogeneic cell-based platforms to revolutionize oncolytic virus therapies, announced that senior management will present a company overview at two upcoming investor conferences.

• 

  FDA Weekly Review: Bayer, Daiichi Sankyo, AstraZeneca, Gamida Cell and More

  8/8/2022

  The FDA has had a busy week, accepting drug applications, approving clinical trials and granting various special designations for Gamida Cell, Cellectis, Scynexis & more. 

• Calidi Biotherapeutics Announces FDA Authorization of IND for a Phase 1 Clinical Trial of NeuroNova in Patients with Recurrent High-Grade Glioma

  8/2/2022

  Calidi Biotherapeutics, Inc. is pleased to announce that City of Hope has received U.S. Food and Drug Administration (FDA) authorization to proceed with a phase 1 physician-sponsored clinical trial that will use Calidi’s licensed oncolytic virotherapy platform, NSC-CRAd-S-pk7.

• Calidi Biotherapeutics Announces Appointment of W.K. Alfred Yung, M.D., to its Medical Advisory Board

  6/28/2022

  Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company that is pioneering the development of stem cell-based delivery of oncolytic viruses, today announced the appointment of W.K. Alfred Yung, M.D., Professor, Neuro-Oncology at the MD Anderson Cancer Center, to its Medical Advisory Board.

• Calidi Biotherapeutics to Present at Jefferies Healthcare Conference

  6/2/2022

  Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company pioneering the development of stem cell-based delivery of oncolytic viruses, today announced that Stephen Thesing, Chief Business Officer, will present a company overview at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 2:00 p.m. ET.

• Calidi Biotherapeutics Granted U.S. Patent for Proprietary Therapeutic Delivery Platform, Strengthening Company’s Intellectual Property Position in Immunotherapy

  5/24/2022

  Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company pioneering the development of stem cell-based delivery of oncolytic viruses, has been granted a new patent (No. US 11,285,194, Combination immunotherapy approach for treatment of cancer) by the U.S. Patent and Trademark Office (USPTO) related to its proprietary SuperNova (SNV) technology platform.

• Calidi Biotherapeutics Announces Appointment of Alfonso "Chito" Zulueta, Former President of International for Eli Lilly, to Its Board of Directors

  2/4/2022

  Calidi Biotherapeutics, Inc. announced today the appointment of Alfonso "Chito" Zulueta to its Board of Directors, effective February 7, 2022.

• Calidi Biotherapeutics Announces Dr. Maciej S. Lesniak Presentation at 13th International Oncolytic Virotherapy Conference

  11/5/2021

  Calidi Biotherapeutics, Inc. announced today that its physician advisor, Maciej S. Lesniak, MD will present at the upcoming International Oncolytic Virotherapy Conference (IOVC), which will be held in hybrid format November 5-7, 2021.

• Calidi Biotherapeutics Announces Presentation at 6th Annual Oncolytic Virotherapy Summit

  10/25/2021

  Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of stem cell-based delivery of oncolytic viruses, announced today its selection as a finalist for presentation during the Innovation Showcase at the upcoming sixth annual Oncolytic Virotherapy Summit.